Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
89Bio Inc
(NQ:
ETNB
)
8.310
-0.040 (-0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
926,443
Open
8.410
Bid (Size)
8.300 (56)
Ask (Size)
8.310 (21)
Prev. Close
8.350
Today's Range
7.970 - 8.455
52wk Range
6.575 - 18.30
Shares Outstanding
75,480,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
Performance
YTD
-26.40%
-26.40%
1 Month
-2.46%
-2.46%
3 Month
-10.74%
-10.74%
6 Month
-23.90%
-23.90%
1 Year
-49.48%
-49.48%
More News
Read More
What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
June 05, 2024
Via
Benzinga
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH
June 05, 2024
Via
Investor's Business Daily
The Week Ahead: What's Next
June 02, 2024
Via
Talk Markets
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress
May 22, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
May 14, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
May 02, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
April 17, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
March 27, 2024
From
89bio, Inc.
Via
GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Via
The Motley Fool
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
March 12, 2024
From
89bio, Inc.
Via
GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
89bio, Inc.
Via
GlobeNewswire
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
March 07, 2024
Via
Benzinga
89bio to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
89bio, Inc.
Via
GlobeNewswire
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
March 04, 2024
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
March 04, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 04, 2024
Via
InvestorPlace
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 04, 2024
Via
Benzinga
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
February 29, 2024
From
89bio, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.